Cargando…

Carbapenem-Resistant Enterobacteriaceae Bloodstream Infection Treated Successfully With High-Dose Meropenem in a Preterm Neonate

Carbapenem-resistant enterobacteriaceae (CRE) bloodstream infections have been rapidly spreading worldwide with a high mortality and pose a challenge to therapeutic decision-making, especially in premature neonates because insufficient empirical antimicrobial therapy is independently associated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Yue-E, Xu, Hai-Yan, Shi, Hai-Yan, van den Anker, John, Chen, Xiao-Yu, Zhao, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518023/ https://www.ncbi.nlm.nih.gov/pubmed/33041807 http://dx.doi.org/10.3389/fphar.2020.566060

Ejemplares similares

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae
por: Petty, Lindsay A, et al.
Publicado: (2018)

Optimal dose of cefotaxime in neonates with early-onset sepsis: A developmental pharmacokinetic model-based evaluation
por: Shang, Zhen-Hai, et al.
Publicado: (2022)

Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae
por: Abe, Ryuichiro, et al.
Publicado: (2019)

1618. Meropenem-vaborbactam vs standard of care for multidrug resistant carbapenem-resistant Enterobacteriaceae
por: Misikir, Helina, et al.
Publicado: (2020)

Socioeconomic Burden of Bloodstream Infections Caused by Carbapenem-Resistant Enterobacteriaceae
por: Zhu, Yunying, et al.
Publicado: (2021)

Clinical and Mortality Risk Factors in Bloodstream Infections with Carbapenem-Resistant Enterobacteriaceae
por: Li, Xiaopeng, et al.
Publicado: (2017)

Optimized Dosing Regimens of Meropenem in Septic Children Receiving Extracorporeal Life Support
por: Wang, Yixue, et al.
Publicado: (2021)

Colonization of the Preterm Neonatal Gut with Carbapenem-resistant Enterobacteriaceae and Its Association with Neonatal Sepsis and Maternal Gut Flora
por: Smith, Abhilasha, et al.
Publicado: (2020)

Population PK/PD modelling of meropenem in preterm newborns based on therapeutic drug monitoring data
por: Zyryanov, Sergey, et al.
Publicado: (2023)

2247. Real-world Experience with Meropenem–Vaborbactam (M/V) for Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections
por: Shields, Ryan K, et al.
Publicado: (2019)

Molecular Epidemiology and Risk Factors of Ventilator-Associated Pneumonia Infection Caused by Carbapenem-Resistant Enterobacteriaceae
por: Gao, Bo, et al.
Publicado: (2019)

Clinical Characteristics and Associated Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bloodstream Infection
por: Ahn, Jin Young, et al.
Publicado: (2023)

1378. Evaluation of the In vitro Activity of Meropenem-Vaborbactam Against Carbapenem-Resistant Enterobacteriaceae, Including Isolates Resistant to Ceftazidime–Avibactam
por: Wilson, William R, et al.
Publicado: (2018)

Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007)
por: Kuti, Joseph L., et al.
Publicado: (2019)

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae
por: Yu, Zhenwei, et al.
Publicado: (2022)

Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model
por: Völler, Swantje, et al.
Publicado: (2019)

479 Clinical outcomes in patients with extended-spectrum-beta-lactamase-producing (ESBL) Enterobacteriaceae bloodstream infections (ESB) treated with carbapenems (CP) and non-carbapenems (NC)
por: Chin, Judy, et al.
Publicado: (2014)

Curcumin-meropenem synergy in carbapenem resistant Klebsiella pneumoniae curcumin-meropenem synergy
por: Gülen, Dumrul, et al.
Publicado: (2021)

Developmental Population Pharmacokinetics and Dosing Optimization of Cefepime in Neonates and Young Infants
por: Zhao, Yang, et al.
Publicado: (2020)

Bloodstream Infections in Patients with Rectal Colonization by Carbapenem-Resistant Enterobacteriaceae: A Prospective Cohort Study
por: Chu, Wenwen, et al.
Publicado: (2022)

High risk of bloodstream infection of carbapenem-resistant enterobacteriaceae carriers in neutropenic children with hematological diseases
por: Liu, Li-Peng, et al.
Publicado: (2023)

A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections
por: Luterbach, Courtney L., et al.
Publicado: (2022)

2266. Management of Ertapenem-Resistant, Meropenem-Susceptible Enterobacteriaceae
por: Srinivas, Pavithra, et al.
Publicado: (2019)

Developmental Population Pharmacokinetics-Pharmacodynamics of Meropenem in Chinese Neonates and Young Infants: Dosing Recommendations for Late-Onset Sepsis
por: Wu, Yue-E, et al.
Publicado: (2022)

External Evaluation of Population Pharmacokinetic Models to Inform Precision Dosing of Meropenem in Critically Ill Patients
por: Yang, Nan, et al.
Publicado: (2022)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
por: Bhavnani, S. M., et al.
Publicado: (2022)

Meropenem-induced pancytopenia in a preterm neonate: a case report
por: Hussain, Kashif, et al.
Publicado: (2021)

Triple Versus Double Therapy for the Treatment of Severe Infections Caused by Carbapenem-Resistant Enterobacteriaceae: A Systematic Review and Meta-Analysis
por: Wang, Lei, et al.
Publicado: (2020)

Systematic review of carbapenem-resistant Enterobacteriaceae causing neonatal sepsis in China
por: Ding, Yijun, et al.
Publicado: (2019)

Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection
por: Kanchanasurakit, Sukrit, et al.
Publicado: (2020)

Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery
por: Lu, Cheng, et al.
Publicado: (2016)

662. Recurrence of Infection and Emergence of Drug Resistance After Treatment with Meropenem/Vaborbactam Compared with Ceftazidime/Avibactam in Carbapenem-Resistant Enterobacteriaceae Infections
por: Ackley, Renee, et al.
Publicado: (2019)

Epidemiological characteristics and risk factors of nosocomial carbapenem-resistant Enterobacteriaceae infections in children
por: Li, Zhe, et al.
Publicado: (2020)

Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan
por: Wang, Jann-Tay, et al.
Publicado: (2015)

Resistance Pattern of Carbapenem on Enterobacteriaceae
por: Pokharel, Khilasa, et al.
Publicado: (2018)

Antibacterial Activity and Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae
por: Yu, Wei, et al.
Publicado: (2021)

Meropenem for children with severe pneumonia: Protocol for a randomized controlled trial
por: Tian, Xue, et al.
Publicado: (2022)

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
por: Wunderink, Richard G., et al.
Publicado: (2018)

TP0586532, a Novel Non-Hydroxamate LpxC Inhibitor: Potentiating Effect on In Vitro Activity of Meropenem against Carbapenem-Resistant Enterobacteriaceae
por: Yoshida, Ippei, et al.
Publicado: (2022)

Bloodstream infections due to Carbapenem-Resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options
por: Zhang, Lining, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_seet1i21o2ch4btdjtu3l921ql